

ARTEMIS

Patients with kidney failure require haemodialysis (HD) to survive. HD requires a vascular access (VA) called arteriovenous fistula (AVF). Unfortunately, AVF is subjected to complications and represent a major health care burden. We developed an easy to use and biodegradable drug delivery system which prevent the occlusion of the VA, main complication of AVF.

ARTEMIS is a unique patented local drug delivery system preventing vein obstruction and increasing quality of life for patients.

TEAM MEMBERS

1. L. Vinet, CHUV, (PhD)
2. N. Mule, UNIGE, Pharmacist (PhD)
3. S. Gou, UNIGE, Pharmacist (PhD)

1 Who are your clients?


The ultimate customers are the patients but vascular surgeons and nephrologists who perform or make decision on VA surgeries will be the entry point on the market.

2 How do you make money?

We will sell our patented Artemis gel through industrial partner(s) or independent marketing & sales distribution channel.

3 What gives you credibility?

The team members are equipped with solid scientific background & supported by emritus surgeons, physicians, & pharmaceutical scientists.



ARTEMIS

Next steps

1. What are you going to do in next 6 months
Look for investment to initiate the preclinical and toxicological studies on big animals.

2. HR needed after the training

We will need consultation on regulatory affairs and financial planning as well as GMP production.

3. What kind of support that you are looking for:
Further training / coaching / funding

Coaching and funding are the main supports we absolutely need at this stage.



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Swiss Confederation
Innosuisse – Swiss Innovation Agency

1



2



3

